Molecular epidemiology of carbapenem-resistant hypervirulent Klebsiella pneumoniae: risk factors and resistance mechanism of ceftazidime/avibactam in China
Bewaard in:
| Gepubliceerd in: | Frontiers in Cellular and Infection Microbiology vol. 15 (Dec 2025), p. 1698033-1698051 |
|---|---|
| Hoofdauteur: | |
| Andere auteurs: | , , , , , , , , , , |
| Gepubliceerd in: |
Frontiers Media SA
|
| Onderwerpen: | |
| Online toegang: | Citation/Abstract Full Text Full Text - PDF |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3286012762 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2235-2988 | ||
| 024 | 7 | |a 10.3389/fcimb.2025.1698033 |2 doi | |
| 035 | |a 3286012762 | ||
| 045 | 2 | |b d20251201 |b d20251231 | |
| 100 | 1 | |a Wang, Na |u 1 Microbiology Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China, 2 Infection Management Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 245 | 1 | |a Molecular epidemiology of carbapenem-resistant hypervirulent Klebsiella pneumoniae: risk factors and resistance mechanism of ceftazidime/avibactam in China | |
| 260 | |b Frontiers Media SA |c Dec 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a BackgroundCarbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) represents a critical public health threat in China, characterized by the convergence of multidrug resistance and hypervirulence. The emergence of ceftazidime/avibactam (CZA) resistance further complicates clinical management. This study aimed to elucidate the molecular epidemiology, risk factors, and resistance mechanisms of CZA resistance in CR-hvKP across China, providing evidence for targeted interventions.MethodsA single-center molecular epidemiological analysis was conducted on 81 Carbapenem-resistant Klebsiella pneumoniae (CRKP) clinical isolates collected. All isolates underwent whole-genome sequencing for MultiLocus Sequence Typing, capsule typing, and identification of resistance genes ( bla KPC-2 and blaNDM-1 ) and virulence factors ( iucA , iroB , rmpA , rmpA 2, and peg- 344). CZA resistance mechanisms were investigated through broth microdilution minimum inhibitory concentration (MIC) testing and bioinformatics analysis. Galleria mellonella infection models were employed to assess virulence potential. Risk factors were analyzed using multivariate regression of clinical variables. Phylogenetic reconstruction employed single-nucleotide polymorphism-based analysis.ResultsST11 accounted for 96.15% (50/52) of CR-hvKP isolates, with K64 being the predominant capsule type (92.31%, 48/52). Additionally, 98.77% (80/81) of CRKP carried ≥1 virulence gene; 64.2% (52/81) of isolates with all five virulence genes exhibited lethality. Galleria mellonella revealed that the survival rate of CR-hvKP was lower than that of carbapenem-resistant non-hypervirulent Klebsiella pneumoniae (p<0.05). Antibiotic usage time (odds ratio [OR]=1.076, 95% confidence interval [CI]: 1.026–1.138), carbapenem antibiotic (OR = 0.117, 95% CI: 0.02266–0.4602), and malignant tumors (OR = 65.1, 95% CI: 7.078–1798) predicted CR-hvKP infection. Transferable bla KPC-2 on IncFII/IncR plasmids conferred CZA resistance (MIC>128 mg/L) without compromising carbapenem resistance, facilitated by a unique genetic context (TnpR_Tn3-ISKpn27- bla KPC-2-ISKpn6).ConclusionChina faces a rapid dissemination of ST11 CR-hvKP clones carrying diversified CZA resistance mechanisms. The convergence of hypervirulence and resistance in ST11 lineages—accelerated by invasive procedures and international transmission—demands enhanced genomic surveillance. CZA resistance arises through multiple pathways, necessitating combination therapies and stewardship programs limiting prolonged CZA use. Our findings underscore an urgent need for rapid diagnostics targeting emergent resistance determinants and infection control measures to contain high-risk clones. | |
| 610 | 4 | |a IBM Corp Clinical & Laboratory Standards Institute | |
| 651 | 4 | |a United States--US | |
| 651 | 4 | |a China | |
| 653 | |a Clinical isolates | ||
| 653 | |a Software | ||
| 653 | |a Public health | ||
| 653 | |a Phylogenetics | ||
| 653 | |a Virulence factors | ||
| 653 | |a Regression analysis | ||
| 653 | |a Epidemiology | ||
| 653 | |a Bioinformatics | ||
| 653 | |a Genomes | ||
| 653 | |a Polymerase chain reaction | ||
| 653 | |a Nucleotide sequence | ||
| 653 | |a Genes | ||
| 653 | |a Convergence | ||
| 653 | |a Multidrug resistance | ||
| 653 | |a Virulence | ||
| 653 | |a Drug resistance | ||
| 653 | |a Ceftazidime | ||
| 653 | |a Plasmids | ||
| 653 | |a Nosocomial infections | ||
| 653 | |a Minimum inhibitory concentration | ||
| 653 | |a Risk factors | ||
| 653 | |a Carbapenems | ||
| 653 | |a Lethality | ||
| 653 | |a Single-nucleotide polymorphism | ||
| 653 | |a Whole genome sequencing | ||
| 653 | |a Multilocus sequence typing | ||
| 653 | |a Galleria mellonella | ||
| 653 | |a Klebsiella pneumoniae | ||
| 700 | 1 | |a Deng, Lexiu |u 3 Respiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Li, Huiying |u 4 Obstetrics and Gynecology Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Jia, Na |u 5 Clinical Laboratory, Tianjin Nankai Tianyun Hospital, Tianjin, China | |
| 700 | 1 | |a Peng, Xiaocui |u 3 Respiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Chang, Jianliang |u 3 Respiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Jiatong Hao |u 3 Respiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Tang, Jianhua |u 6 Department of Pharmacy, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Lei, Chunmei |u 1 Microbiology Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Wang, Bu |u 3 Respiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Liu, Jianhua |u 3 Respiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 700 | 1 | |a Zhang, Wei |u 7 Central Laboratory, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China | |
| 773 | 0 | |t Frontiers in Cellular and Infection Microbiology |g vol. 15 (Dec 2025), p. 1698033-1698051 | |
| 786 | 0 | |d ProQuest |t Public Health Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3286012762/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3286012762/fulltext/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3286012762/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch |